Viloxazine extended-release is a novel nonstimulant under investigation as a potential treatment for attention-deficit/hyperactivity disorder (ADHD). Given the potential for viloxazine extended-release to be co-administered with stimulant ADHD pharmacotherapies, this trial investigated the pharmacokinetics and safety of combination viloxazine extended-release + lisdexamfetamine dimesylate (lisdexamfetamine) versus viloxazine extended-release and lisdexamfetamine alone.

中文翻译：

---

在健康成人中联合使用维洛嗪缓释 (SPN-812) 和 Lisdexamfetamine 的药代动力学。

Viloxazine 缓释剂是一种正在研究中的新型非兴奋剂，可作为注意力缺陷/多动障碍 (ADHD) 的潜在治疗方法。鉴于 viloxazine 缓释剂与兴奋剂 ADHD 药物疗法共同给药的潜力，本试验研究了 viloxazine 缓释剂 + lisdexamfetamine 二甲磺酸盐 (lisdexamfetamine) 与 viloxazine 缓释剂和 lisdexamfetamine 单独使用的药代动力学和安全性。